Pharmaxis Cancer Drug Shows Increased Survival in Preclinical Models of Aggressive Pancreatic Cancer
29th
Aug 23
Release Date: 29/08/2023 8:42am
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced publication in the prestigious journal Nature Cancer of preclinical results showing pan-Lysyl Oxidase (pan-LOX) inhibitor PXS-5505 increases survival by 35% compared to chemotherapy treatment alone in the treatment of pancreatic ductal adenocarcinomas.
Research in mouse models, led by a team at the Garvan Institute of Medical Research in Sydney, Australia, also showed PXS-5505 combined with chemotherapy reduced the spread of the cancer to other organs such as the liver by 45%.
Categories: News and Media